Virax Biolabs Group annual total assets
2021
2022
2023
2024
2025
2026
Virax Biolabs Group Total Assets Growth & History (VRAX)
Virax Biolabs Group's total assets was $8.3M for fiscal 2026.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $8.3M | $1.9M | +29.53% |
| 2025 | 2025-03-31 | $6.4M | $942,934 | +17.19% |
| 2024 | 2024-03-31 | $5.5M | −$4.3M | −44.11% |
| 2023 | 2023-03-31 | $9.8M | $9.8M | +20046.22% |
| 2022 | 2022-03-31 | $48,706 | $9,085 | +22.93% |
| 2021 | 2021-03-31 | $39,621 | — | — |
Virax Biolabs Group quarterly total assets
Q4.21
Q4.22
Q4.23
Q4.24
Q4.25
Q2.26
Q4.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | $8.3M | $1.9M | +29.53% |
| Q2 2026 | 2025-09-30 | $5.7M | — | — |
| Q4 2025 | 2025-03-31 | $6.4M | $942,934 | +17.19% |
| Q4 2024 | 2024-03-31 | $5.5M | −$4.3M | −44.11% |
| Q4 2023 | 2023-03-31 | $9.8M | $9.8M | +20046.22% |
| Q4 2022 | 2022-03-31 | $48,706 | $9,085 | +22.93% |
| Q4 2021 | 2021-03-31 | $39,621 | — | — |
Virax Biolabs Group total assets trends
Over the last five fiscal years, Virax Biolabs Group's total assets increased from $39,621 to $8.3M, a change of $8.3M. The latest reported quarter, Q4 2026, shows $8.3M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group source filings ↗